Katerina Chatzi Ph.D co-founded Promakhos Therapeutics in 2021 and secured $2.55M in funding for the company. Previously she was a postdoc in the department of Molecular and cellular biology at Harvard. Katerina has extensive experience and publications on how bacterial molecules (secretory molecules and metabolites) act as modulators of innate immunity. Her experience led to the scientific foundation of Promakhos Therapeutics.
Speaking In
11:00 AM - 1:00 PM
Tuesday, June 6
